Literature DB >> 20018188

C-mip interacts with the p85 subunit of PI3 kinase and exerts a dual effect on ERK signaling via the recruitment of Dip1 and DAP kinase.

Maud Kamal1, Andre Pawlak, Fatima BenMohamed, Asta Valanciuté, Karine Dahan, Marina Candelier, Philippe Lang, Georges Guellaën, Djillali Sahali.   

Abstract

In naive T cells, Lck exerts a negative control on the ERK/MAPK pathway. We show that c-mip (c-maf inducing protein) interacts with the p85 subunit of PI3 kinase and inactivates Lck, which results in Erk1/2 and p38 MAPK activation. This effect is not enough to activate AP1 given the inability of ERK to migrate into the nucleus and to transactivate its target genes. We demonstrate that c-mip interacts with Dip1 and upregulates DAPK, which blocks the nuclear translocation of ERK1/2. This dual effect of c-mip is unique and might represent a potential mechanism to prevent the development of an immune response. 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20018188     DOI: 10.1016/j.febslet.2009.12.015

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

Review 1.  Immunopathogenesis of idiopathic nephrotic syndrome with relapse.

Authors:  Djillali Sahali; Kelhia Sendeyo; Melanie Mangier; Vincent Audard; Shao Yu Zhang; Philippe Lang; Mario Ollero; Andre Pawlak
Journal:  Semin Immunopathol       Date:  2014-01-09       Impact factor: 9.623

Review 2.  Physiopathology of idiopathic nephrotic syndrome: lessons from glucocorticoids and epigenetic perspectives.

Authors:  Valéry Elie; May Fakhoury; Georges Deschênes; Evelyne Jacqz-Aigrain
Journal:  Pediatr Nephrol       Date:  2011-06-28       Impact factor: 3.714

Review 3.  Genetic advances in the study of speech and language disorders.

Authors:  D F Newbury; A P Monaco
Journal:  Neuron       Date:  2010-10-21       Impact factor: 17.173

4.  Human neonatal naive CD4+ T cells have enhanced activation-dependent signaling regulated by the microRNA miR-181a.

Authors:  Amy C Palin; Vasavi Ramachandran; Swati Acharya; David B Lewis
Journal:  J Immunol       Date:  2013-02-13       Impact factor: 5.422

5.  Molecular and genetic basis of inherited nephrotic syndrome.

Authors:  Maddalena Gigante; Matteo Piemontese; Loreto Gesualdo; Achille Iolascon; Filippo Aucella
Journal:  Int J Nephrol       Date:  2011-09-06

Review 6.  Death-associated protein kinase: A molecule with functional antagonistic duality and a potential role in inflammatory bowel disease (Review).

Authors:  Sara Steinmann; Kristina Scheibe; Katharina Erlenbach-Wuensch; Clemens Neufert; Regine Schneider-Stock
Journal:  Int J Oncol       Date:  2015-05-11       Impact factor: 5.650

7.  Expression of CMIP in podocytes is restricted to specific classes of lupus nephritis.

Authors:  Khedidja Bouachi; Anissa Moktefi; Shao-Yu Zhang; Julie Oniszczuk; Kelhia Sendeyo; Philippe Remy; Vincent Audard; Andre Pawlak; Mario Ollero; Djillali Sahali
Journal:  PLoS One       Date:  2018-11-15       Impact factor: 3.240

8.  CMIP is a negative regulator of T cell signaling.

Authors:  Julie Oniszczuk; Kelhia Sendeyo; Cerina Chhuon; Berkan Savas; Etienne Cogné; Pauline Vachin; Carole Henique; Ida Chiara Guerrera; Giuseppe Astarita; Vincent Frontera; Andre Pawlak; Vincent Audard; Dil Sahali; Mario Ollero
Journal:  Cell Mol Immunol       Date:  2019-08-08       Impact factor: 11.530

9.  MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression.

Authors:  Jing Zhang; Lei Liu; Yunyan Sun; Jiandong Xiang; Dongmei Zhou; Li Wang; Huali Xu; Xiaoming Yang; Na Du; Meng Zhang; Qin Yan; Xiaowei Xi
Journal:  Oncotarget       Date:  2016-05-03

10.  CMIP interacts with WT1 and targets it on the proteasome degradation pathway.

Authors:  Shao-Yu Zhang; Qingfeng Fan; Anissa Moktefi; Virginie Ory; Vincent Audard; Andre Pawlak; Mario Ollero; Dil Sahali; Carole Henique
Journal:  Clin Transl Med       Date:  2021-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.